en
Scientific article
French

Dupilumab : au-delà de la dermatite atopique, les principales utilisations hors indication en dermatologie

Published inRevue médicale suisse, vol. 19, no. 820, p. 606-613
Publication date2023-03-29
Abstract

Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor inhibiting the signaling of interleukin-4 and interleukin-13, two major cytokines in type 2 inflammatory diseases such as atopic dermatitis, asthma and nasosinusal polyposis. Since its approval for atopic dermatitis in 2017, the molecule has occasionally been used off-label in several dermatological conditions where standard treatments are often disappointing.Furthermore, what emerges from the data currently in the literature is a favourable safety profile with few, reversible side effects.

engfre
Keywords
  • Humans
  • Dermatitis, Atopic / drug therapy
  • Off-Label Use
  • Antibodies, Monoclonal / adverse effects
  • Dermatology
  • Treatment Outcome
  • Severity of Illness Index
Citation (ISO format)
RUSSO, Giuseppe, LAFFITTE, Emmanuel Alexis. Dupilumab : au-delà de la dermatite atopique, les principales utilisations hors indication en dermatologie. In: Revue médicale suisse, 2023, vol. 19, n° 820, p. 606–613. doi: 10.53738/REVMED.2023.19.820.606
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 09/30/2024
Identifiers
ISSN of the journal1660-9379
8views
0downloads

Technical informations

Creation12/22/2023 8:46:04 AM
First validation04/09/2024 8:12:17 AM
Update time04/09/2024 8:12:17 AM
Status update04/09/2024 8:12:17 AM
Last indexation04/09/2024 8:12:36 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack